Physician profile
Mark Snavely
NPI 1942678958
$10,520.23
in general payments reported to CMS, 2019-2025
24 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $669 · 2022: $1,556 · 2023: $2,541 · 2024: $2,990 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,830 · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,829.91 |
| Education | $465.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,519.40 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,890.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,119.34 | 2021-2025 | Dupixent |
| Genzyme Corporation | $800.89 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $795.68 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $649.42 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $421.87 | 2021-2025 | |
| Lilly USA, LLC | $404.77 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $283.16 | 2021-2025 | Opzelura |
| Pfizer INC. | $268.43 | 2022-2025 | |
| Leo Pharma INC. | $210.05 | 2022-2023 | Adbry |
| Dermavant Sciences, INC. | $187.17 | 2023-2024 | Vtama |
| Ucb, INC. | $171.94 | 2023-2025 | Bimzelx |
| Amgen INC. | $169.45 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $120.83 | 2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $118.58 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $98.17 | 2022 | |
| Verrica Pharmaceuticals INC. | $72.50 | 2024-2025 | Ycanth |
| Botanix Sb INC | $48.51 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $46.79 | 2024-2025 | Nemluvio |
| Almirall LLC | $46.59 | 2022-2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.67 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.21 | 2024 | Arazlo, Cabtreo |
| Celgene Corporation | $19.88 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Snavely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.